Biomarkers /
MLLT10
Overview
Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog; Drosophila); translocated to, 10 (MLLT10; also known as AF10) is a gene that encodes a protein that functions in transcriptional regulation. Fusions and missense mutations are observed in cancers such as intestinal cancer, lung cancer, and skin cancer.
MLLT10 is altered in 0.26% of all cancers with high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, endometrial serous adenocarcinoma, and lung adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in MLLT10 are MLLT10 V256F (0.77%), MLLT10 X664_splice (0.25%), MLLT10 A1064S (0.30%), MLLT10 A395S (0.39%), and MLLT10 A575T (0.30%) [3].
Clinical Trials
Significance of MLLT10 in Diseases
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.